Free Trial
TSE:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Medicenna Therapeutics logo
C$1.05 -0.05 (-4.55%)
As of 03:59 PM Eastern

About Medicenna Therapeutics Stock (TSE:MDNA)

Key Stats

Today's Range
C$1.05
C$1.12
50-Day Range
C$0.85
C$1.22
52-Week Range
C$0.85
C$2.98
Volume
13,600 shs
Average Volume
53,993 shs
Market Capitalization
C$78.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

Silver Demand Is Soaring-Supply Can't Keep Up
Silver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. Industrial demand is rising fast, but new supply isn't keeping pace. For investors, that opens the door to one key question: who already has it? One project in N. America just reported high-grade results at a time when ounces in the ground are becoming harder to find-and more valuable.
Medicenna’s MDNA11 Shows Promising Cancer Treatment Results
Medicenna Reports Promising Results with MDNA11
See More Headlines

MDNA Stock Analysis - Frequently Asked Questions

Medicenna Therapeutics' stock was trading at C$1.65 at the beginning of 2025. Since then, MDNA stock has decreased by 36.4% and is now trading at C$1.05.
View the best growth stocks for 2025 here
.

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Gilead Sciences (GILD), OPKO Health (OPK), Air Canada (AC), Athersys (ATHX), Birchcliff Energy (BIR) and Canadian Natural Resources (CNQ).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
TSE:MDNA
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-25,979,688.98
Net Margins
-533,640.00%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$4,868.39
Price / Sales
16,135.90
Cash Flow
C$0.91 per share
Price / Cash Flow
1.15
Book Value
C$0.26 per share
Price / Book
4.02

Miscellaneous

Free Float
N/A
Market Cap
C$78.56 million
Optionable
Not Optionable
Beta
1.21
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (TSE:MDNA) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners